Advancement to Phase 2 follows positive interim Phase 1b data in Atopic Dermatitis, demonstrating a robust efficacy and safety profileParallel Phase 2a initiated studies evaluating ENV-294, a first-in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback